Lumira Ventures

Type

Venture Capital

Status

Active

Location

Toronto, Canada

Total investments

99

Average round size

25M

Portfolio companies

56

Rounds per year

2.83

Lead investments

16

Follow on index

0.43

Exits

20

Stages of investment
Private EquityEarly Stage VentureLate Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsMedical DeviceMedicalDeveloper PlatformPharmaceuticalTherapeuticsBiopharmaDiabetes

Summary

Lumira Ventures is the famous VC, which was founded in 1989. The main department of described VC is located in the Toronto. The fund was located in North America if to be more exact in Canada.

The overall number of key employees were 12.

The top amount of exits for fund were in 2019. This Lumira Ventures works on 12 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 2-6 deals per year. The real fund results show that this VC is 7 percentage points more often commits exit comparing to other companies. The high activity for fund was in 2018.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Lumira Ventures, startups are often financed by Fonds de solidaritu00e9 FTQ, Arboretum Ventures, SV Health Investors. The meaningful sponsors for the fund in investment in the same round are Fonds de solidaritu00e9 FTQ, Aperture Venture Partners, SV Health Investors. In the next rounds fund is usually obtained by M. H. Carnegie & Co., Fonds de solidaritu00e9 FTQ, Arboretum Ventures.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the various public portfolio startups of the fund, we may underline Cardiac Dimensions, Thrasos, Celtaxsys Among the most popular fund investment industries, there are Biopharma, Health Diagnostics. The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtechHealthcare
Stage focus
Seed
Geo focus
CanadaUnited States

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
USD 255000000
Fund raised date
2021-07-26

Analytics

Total investments
99
Lead investments
16
Exits
20
Rounds per year
2.83
Follow on index
0.43
Investments by industry
  • Biotechnology (75)
  • Health Care (60)
  • Medical Device (30)
  • Medical (27)
  • Therapeutics (27)
  • Show 21 more
Investments by region
  • United States (56)
  • Canada (40)
  • United Kingdom (2)
Peak activity year
2018

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
13
Avg. valuation at time of investment
14M
Group Appearance index
0.83
Avg. company exit year
10
Avg. multiplicator
1.23
Strategy success index
0.70

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Deka Biosciences 28 Sep 2023 Biotechnology, Health Care Early Stage Venture 20M United States, District of Columbia, Washington
Specific Biologics 16 Dec 2021 Biotechnology Seed United States, California, Ontario

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.